Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Wu

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Annals of Surgery|May 25, 2011
Improving cutaneous scar formation by controlling the mechanical environment: large animal and phase I studiesGeoffrey C Gurtner, Reinhold H Dauskardt, Victor W Wong, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 30, 2019
SCF<sup>FBXO22</sup> targets HDM2 for degradation and modulates breast cancer cell invasion and metastasisJin Bai, Kenneth Wu, Meng-Han Cao, et al.
The Journal of Biological Chemistry|May 22, 2003
DEN1 is a dual function protease capable of processing the C terminus of Nedd8 and deconjugating hyper-neddylated CUL1Kenneth Wu, Kosj Yamoah, Georgia Dolios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE TrialDavid F Penson, Andrew J Armstrong, Raoul Concepcion, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Reply to M.A.N. Şendur et al and J. MichelsDavid F Penson, Andrew J Armstrong, Raoul Concepcion, et al.
Molecular Biology of the Cell|May 14, 2010
Ubr1 and Ubr2 function in a quality control pathway for degradation of unfolded cytosolic proteinsNadinath B Nillegoda, Maria A Theodoraki, Atin K Mandal, et al.
Future Oncology (London, England)|March 25, 2020
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaPeter Hillmen, Jennifer R Brown, Barbara F Eichhorst, et al.
Journal of Proteome Research|January 18, 2020
IKK-Mediated Regulation of the COP9 Signalosome via Phosphorylation of CSN5Jingzi Zhang, Ruoyu Zhao, Clinton Yu, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 19, 2021
Inhibitors of cullin-RING E3 ubiquitin ligase 4 with antitumor potentialKenneth Wu, Khoi Q Huynh, Iris Lu, et al.
British Journal of Haematology|December 16, 2021
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 studyGavin Cull, Jan A Burger, Stephen Opat, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Annals of Surgery|May 25, 2011
Improving cutaneous scar formation by controlling the mechanical environment: large animal and phase I studiesGeoffrey C Gurtner, Reinhold H Dauskardt, Victor W Wong, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 30, 2019
SCF<sup>FBXO22</sup> targets HDM2 for degradation and modulates breast cancer cell invasion and metastasisJin Bai, Kenneth Wu, Meng-Han Cao, et al.
The Journal of Biological Chemistry|May 22, 2003
DEN1 is a dual function protease capable of processing the C terminus of Nedd8 and deconjugating hyper-neddylated CUL1Kenneth Wu, Kosj Yamoah, Georgia Dolios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE TrialDavid F Penson, Andrew J Armstrong, Raoul Concepcion, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Reply to M.A.N. Şendur et al and J. MichelsDavid F Penson, Andrew J Armstrong, Raoul Concepcion, et al.
Molecular Biology of the Cell|May 14, 2010
Ubr1 and Ubr2 function in a quality control pathway for degradation of unfolded cytosolic proteinsNadinath B Nillegoda, Maria A Theodoraki, Atin K Mandal, et al.
Future Oncology (London, England)|March 25, 2020
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaPeter Hillmen, Jennifer R Brown, Barbara F Eichhorst, et al.
Journal of Proteome Research|January 18, 2020
IKK-Mediated Regulation of the COP9 Signalosome via Phosphorylation of CSN5Jingzi Zhang, Ruoyu Zhao, Clinton Yu, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 19, 2021
Inhibitors of cullin-RING E3 ubiquitin ligase 4 with antitumor potentialKenneth Wu, Khoi Q Huynh, Iris Lu, et al.
British Journal of Haematology|December 16, 2021
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 studyGavin Cull, Jan A Burger, Stephen Opat, et al.
Pageof 9